A message from Dr. Steven Treon, MD, Ph.D: I would like to share with you and the IWMF membership the paper which was just published in BLOOD as a FIRST EDITION. It describes the course of 6 WM patients on ibrutinib who contracted COVID-19.
Please feel free to share with the membership. We are beginning two prospective multicenter trials in COVID-19 patients, one with ibrutinib and the other with zanubrutinib. Much of what we have learned about the Toll-receptor/MYD88 pathway in WM enabled us to re-purpose much of this knowledge to COVID-19 that exploits this pathway for producing lung injury. The IWMF enabled much of this learning, and we are grateful that the findings from those studies could be re-purposed against COVID-19.
Click here to view the article: